TCR2 Therapeutics MUN:2K7 株式レポート TCR2 Therapeutics Inc.
MUN:2K7 株式レポート
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events 2K7 株式概要 TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
TCR2 Therapeutics Inc. 競合他社 価格と性能
の歴代最高値、変動、値下がりまとめTCR2 Therapeutics 過去の株価 現在の株価 US$2.49 52週高値 US$6.05 52週安値 US$2.49 ベータ 1.78 11ヶ月の変化 0% 3ヶ月変化 n/a 1年変化 n/a 33年間の変化 n/a 5年間の変化 n/a IPOからの変化 -81.32%
最新ニュース Adaptimmune Therapeutics plc (NasdaqGS:ADAP) completed the acquisition of TCR2 Therapeutics Inc. (NasdaqGS:TCRR) from a group of shareholders.
TCR2 Therapeutics Inc. Appoints Peter Olagunju as Chief Operating Officer Jan 04
Tcr2 Therapeutics Inc. Announces Positive Topline Results from the Phase 1 Portion of the Gavo-Cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors Sep 29
TCR2 Therapeutics Inc., Annual General Meeting, Oct 14, 2022 Sep 02
TCR2 Therapeutics Inc. Appoints Eric Sullivan as Chief Financial Officer Jun 28 TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from Russell 2000 Dynamic Index 最新情報をもっと見る Adaptimmune Therapeutics plc (NasdaqGS:ADAP) completed the acquisition of TCR2 Therapeutics Inc. (NasdaqGS:TCRR) from a group of shareholders.
TCR2 Therapeutics Inc. Appoints Peter Olagunju as Chief Operating Officer Jan 04
Tcr2 Therapeutics Inc. Announces Positive Topline Results from the Phase 1 Portion of the Gavo-Cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors Sep 29
TCR2 Therapeutics Inc., Annual General Meeting, Oct 14, 2022 Sep 02
TCR2 Therapeutics Inc. Appoints Eric Sullivan as Chief Financial Officer Jun 28 TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from Russell 2000 Dynamic Index 株主還元 2K7 DE Biotechs DE 市場 7D 0% -2.2% 1.1% 1Y n/a -17.1% 13.5%
株主還元を見る
業界別リターン: 2K7がGerman Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。
リターン対市場: 2K7 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。
価格変動 Is 2K7's price volatile compared to industry and market? 2K7 volatility 2K7 Average Weekly Movement n/a Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
安定した株価: 2K7過去 3 か月間に大きな価格変動はありませんでした。
時間の経過による変動: 過去 1 年間の2K7のボラティリティの変化を判断するには データが不十分です 。
TCR2 Therapeutics Inc. 基礎のまとめ TCR2 Therapeutics の収益と売上を時価総額と比較するとどうか。 2K7 基礎統計学 時価総額 €95.44m 収益（TTM） -€115.27m 売上高(TTM ) n/a
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 2K7 損益計算書（TTM） 収益 US$0 売上原価 US$0 売上総利益 US$0 その他の費用 US$114.71m 収益 -US$114.71m
一株当たり利益（EPS） -2.97 グロス・マージン 0.00% 純利益率 0.00% 有利子負債／自己資本比率 0%
2K7 の長期的なパフォーマンスは？
過去の実績と比較を見る
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
